Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M87,164Revenue $M8,264Net Margin (%)8.6Altman Z-Score1.7
Enterprise Value $M116,651EPS $2.7Operating Margin %23.6Piotroski F-Score5
P/E(ttm)118Beneish M-Score-2.2Pre-tax Margin (%)11.0Higher ROA y-yY
Price/Book14.210-y EBITDA Growth Rate %10.5Quick Ratio1.2Cash flow > EarningsY
Price/Sales9.55-y EBITDA Growth Rate %55.9Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow50.5y-y EBITDA Growth Rate %119ROA % (ttm)2.4Higher Current Ratio y-yN
Dividend Yield %--PEG2.1ROE % (ttm)14.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M343ROIC % (ttm)6.2Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXKen Fisher 2015-06-30 Buy $197.39 - $241.73
($221.34)
$ 254.2815%New holding1,828
VRXBill Ackman 2015-03-31 Buy 25.84%$142.83 - $204.69
($177.4)
$ 254.2843%New holding19,473,933
VRXWallace Weitz 2015-03-31 Reduce-1.84%$142.83 - $204.69
($177.4)
$ 254.2843%Reduce 33.46%917,261
VRXSteve Mandel 2015-03-31 Reduce-1.62%$142.83 - $204.69
($177.4)
$ 254.2843%Reduce 32.50%5,569,460
VRXJohn Paulson 2015-03-31 Add1.6%$142.83 - $204.69
($177.4)
$ 254.2843%Add 293.70%2,050,000
VRXGlenn Greenberg 2015-03-31 Reduce-1.24%$142.83 - $204.69
($177.4)
$ 254.2843%Reduce 4.07%5,877,016
VRXGeorge Soros 2015-03-31 Sold Out -0.95%$142.83 - $204.69
($177.4)
$ 254.2843%Sold Out0
VRXChris Davis 2015-03-31 Reduce-0.74%$142.83 - $204.69
($177.4)
$ 254.2843%Reduce 46.50%1,877,040
VRXLou Simpson 2015-03-31 Add0.71%$142.83 - $204.69
($177.4)
$ 254.2843%Add 5.81%1,898,540
VRXJoel Greenblatt 2015-03-31 Reduce-0.26%$142.83 - $204.69
($177.4)
$ 254.2843%Reduce 77.83%65,531
VRXRuane Cunniff 2015-03-31 Reduce-0.18%$142.83 - $204.69
($177.4)
$ 254.2843%Reduce 0.71%34,089,378
VRXPrivate Capital 2015-03-31 Add0.06%$142.83 - $204.69
($177.4)
$ 254.2843%Add 0.86%295,320
VRXGlenn Greenberg 2014-12-31 Reduce-2.23%$113.56 - $146.39
($134.66)
$ 254.2889%Reduce 6.98%6,126,609
VRXSteve Mandel 2014-12-31 Reduce-1.39%$113.56 - $146.39
($134.66)
$ 254.2889%Reduce 24.90%8,250,886
VRXWallace Weitz 2014-12-31 Reduce-1.2%$113.56 - $146.39
($134.41)
$ 254.2889%Reduce 18.50%1,378,606
VRXJoel Greenblatt 2014-12-31 Buy 0.34%$113.56 - $146.39
($134.66)
$ 254.2889%New holding295,632
VRXRuane Cunniff 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 254.2889%Reduce 0.47%34,331,973
VRXLou Simpson 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 254.2889%Reduce 1.19%1,794,227
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 254.28114%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 254.28114%Add 12.40%1,815,916
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rosiello Robert L.Executive Vice President 2015-06-12Buy12,900$232.519.36view
UBBEN JEFFREY W 2015-06-10Sell4,200,000$220.2415.46view
Farmer Ronald HaroldDirector 2015-06-09Buy1,000$260.63-2.44view
Mirovsky PavelEVP, Pres. & GM Valeant EMENA 2015-06-02Sell38,000$238.016.84view
Whitaker Anne ClemDirector 2015-05-26Buy7,500$234.678.36view
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-05-04Sell90,938$222.5414.26view
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-03-02Sell90,939$200.0127.13view
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.4858.45view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0681.55view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.7374.49view

Quarterly/Annual Reports about VRX:

News about VRX:

Articles On GuruFocus.com
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
Gabelli ABC Fund Second Quarter Letter Jul 27 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
Andreas Halvorsen Sells More Than Half of His Stake in Valeant Jun 18 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
Lou Simpson Adds Precision Castparts to Portfolio in First Quarter Jun 08 2015 
Jeff Ubben Adds to Stakes in Microsoft, Halliburton, Baker Hughes in First Quarter Jun 04 2015 
An Exclusive GuruFocus Interview With Value Investor Wally Weitz Jun 03 2015 
John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes Jun 01 2015 

More From Other Websites
Ackman ‘Wolf Pack' Sent Allergan to Foreigners, Ex-CEO Says Jul 30 2015
Will Jazz Pharma's Stock Awake With Q2 Earnings? Jul 30 2015
Ackman’s ‘Wolf Pack’ Sent Allergan to Foreign Hands, Ex-CEO Says Jul 30 2015
Senate Uses Valeant Pharma, Burger King, AB InBev To Expose Unequal Corporate Taxation In U.S. Jul 30 2015
Taxes Drove Valeant, Burger King Deals, Senate Report Says Jul 30 2015
Valeant Pharmaceuticals International, Inc. Earnings Analysis: By the Numbers Jul 30 2015
Pharming Reports on Financial Results First Half Year 2015 Jul 30 2015
Tax Savings Drove Valeant, Burger King Deals, Senate Report Says Jul 29 2015
Valeant Tells Congress a Very Different Tax Tale Than Investors Jul 29 2015
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report Jul 28 2015
Which Big-Cap Stocks Are Defying Market Pressure? Jul 27 2015
Morgan Stanley Lifts Target On Valeant From $235 To $284 Jul 27 2015
RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals Jul 27 2015
Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market Jul 24 2015
Biogen's Big-Volume Plunge Marks End Of 5-Year Run Jul 24 2015
Valeant (VRX) Beats on Q2 Earnings & Revenues, Ups View - Analyst Blog Jul 24 2015
Valeant Clears Buy Point, Paces Top Medical Stocks Jul 23 2015
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates Jul 23 2015
Stock Market Today - 07/23/15 Jul 23 2015
Dealpolitik: Activism Makes Corporate Governance More Complex at Zoetis Jul 23 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK